Merrell Dow Pharmaceuticals Inc. v. Thompson Ex Rel. Thompson Case Brief

Merrell Dow Pharmaceuticals Inc. v. Thompson Ex Rel. Thompson

478 U.S. 804 | 106 S. Ct. 3229 | 92 L. Ed. 2d 650 | 1986 U.S. LEXIS 143 | 54 U.S.L.W. 5088

Full access

Unlock the video and quiz

The written brief is free to read below. Subscribe to watch the video explainer and take the quiz.

Takeaway

In short, this case holds that a state tort claim does not arise under federal law merely because it incorporates a federal statutory violation, when Congress did not intend to create a private federal remedy for that violation.

Background

Canadian and Scottish residents sued Merrell Dow in Ohio state court, alleging that mothers’ use of the anti-nausea drug Bendectin during pregnancy caused their children’s birth defects. Their complaints sought damages under several state-law theories, including negligence, warranty, strict liability, fraud, and gross negligence.

One count alleged that Bendectin was “misbranded” under the Federal Food, Drug, and Cosmetic Act (FDCA) because its labeling did not adequately warn of the drug’s dangers. The plaintiffs alleged that the FDCA violation created a rebuttable presumption of negligence and proximately caused the children’s injuries.

Merrell Dow removed the cases to federal district court, asserting federal-question jurisdiction. The District Court denied the plaintiffs’ remand motion, reasoning that the FDCA-based count arose under federal law under Smith v. Kansas City Title & Trust Co., and then dismissed on forum non conveniens grounds. The Sixth Circuit reversed, holding that the FDCA supplied only one possible measure of negligence in state tort claims and that the FDCA did not create a private right of action. The Supreme Court granted certiorari and affirmed the Sixth Circuit’s jurisdictional result.

Issues

Issue #1

Whether a state-law tort claim arises under federal law for purposes of 28 U.S.C. § 1331 when the claim uses violation of a federal statute as an element, but Congress did not intend to create a private federal cause of action for violating that statute.

Holding

No. Assuming the FDCA provides no private federal cause of action, alleging an FDCA violation as an element of a state-law negligence claim does not make the claim one arising under federal law.

Reasoning

Federal-question jurisdiction is governed by the well-pleaded-complaint rule. A case ordinarily arises under the law that creates the cause of action, and a federal defense cannot create jurisdiction. Although a state-created claim can sometimes arise under federal law when the plaintiff’s right to relief necessarily depends on a substantial and disputed federal issue, the mere presence of a federal issue is not automatically enough.

The Court assumed, as both parties did, that the FDCA creates no private federal remedy for persons injured by violations of its labeling provisions. That assumption matters because the decision not to authorize a private federal remedy reflects Congress’s judgment about the role of private federal litigation in enforcing the statute. Federal courts should not effectively circumvent that judgment by exercising jurisdiction merely because state law treats the same statutory violation as evidence of negligence, a rebuttable presumption, or a proximate cause of injury.

In this setting, Congress’s decision to withhold a private federal remedy means that the embedded FDCA issue is not sufficiently substantial to support § 1331 jurisdiction. The Court did not adopt a mechanical rule that every federal issue in a state claim defeats or establishes jurisdiction. Instead, it followed the pragmatic approach of prior cases, which requires attention to congressional intent, the federal-state balance, and the proper administration of the federal courts.

Merrell Dow’s interest in uniform interpretation of the FDCA did not change the result. If state-law claims based on FDCA violations threaten the federal regulatory scheme, the pertinent argument is that federal law preempts the state cause of action—not that every such state claim belongs in federal district court. Moreover, the Supreme Court may review state-court judgments that decide federal questions, which reduces the need to create original federal jurisdiction here.

The novelty of the particular FDCA question, including whether the Act applied to sales abroad, also could not supply jurisdiction. Making jurisdiction depend on a district court’s case-by-case assessment of how novel or difficult an embedded federal issue appears would undermine predictable jurisdictional rules and improperly elevate a state tort claim into a federal cause of action.

Dissents

Justice Brennan

Reasoning

Justice Brennan, joined by Justices White, Marshall, and Blackmun, concluded that the FDCA-based count fell comfortably within the rule of Smith v. Kansas City Title & Trust Co. Under Smith, federal jurisdiction exists when a plaintiff’s state-created right to relief depends on the construction or application of federal law and the federal claim is colorable. As pleaded, the plaintiffs’ fourth count alleged that an FDCA violation established Merrell Dow’s negligence and directly caused the injuries; resolving that count therefore necessarily required deciding a genuine federal statutory question.

The dissent rejected the majority’s inference that Congress’s failure to create a private federal remedy also negated federal jurisdiction over a state claim incorporating the federal standard. Those are distinct questions. A decision not to create a federal cause of action may reflect a choice to limit private enforcement, but it does not logically show that Congress preferred state courts over federal courts when state law independently makes violation of the federal standard actionable.

In Justice Brennan’s view, the purposes of § 1331 favored jurisdiction. Federal courts possess greater experience with federal law, can promote more uniform interpretations, and provide a forum less likely to misread or underenforce federal standards. Those concerns apply just as strongly when federal law is an essential element of a state-law claim as when federal law itself creates the cause of action.

The FDCA’s enforcement design reinforced that conclusion. Congress assigned primary regulatory responsibility to the Food and Drug Administration and provided for federal-court enforcement of the Act’s express remedies. If a state-law private remedy based on an FDCA violation is not preempted, the dissent saw no basis for allowing that remedy in state court while denying a federal forum that is especially suited to interpret the FDCA. If Congress meant to bar all private enforcement, the proper doctrine would be preemption, not a narrowing of federal-question jurisdiction.